Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Trial details
- Registry ID
- NCT04913675
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.NCT04913675 | VIR | Phase 3 | Terminated | 2022-07-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |